GlassScriptPhysician profile
Moshir Jacob
NPI 1245237007
$4,308.61
in general payments reported to CMS, 2019-2025
27 companies · $822 in 2025
The $822 reported for 2025 was more than what 82% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,048 · 2020: $201 · 2021: $377 · 2022: $894 · 2023: $467 · 2024: $500 · 2025: $822.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,788.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,788.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $593.75 | 2019-2022 | |
| Boston Scientific Corporation | $432.84 | 2022-2025 | General - Pain Management |
| Inari Medical, INC. | $308.30 | 2023-2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Astrazeneca Pharmaceuticals LP | $264.31 | 2019-2025 | Breztri, Airsupra |
| Novo Nordisk INC | $257.07 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Abbvie INC. | $255.16 | 2022-2023 | |
| Medtronic, INC. | $228.48 | 2022-2024 | Venaseal |
| Janssen Scientific Affairs, LLC | $205.73 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $205.16 | 2022-2023 | |
| Pfizer INC. | $165.52 | 2019-2025 | |
| Abbott Laboratories | $124.89 | 2021 | |
| Sunovion Pharmaceuticals INC. | $124.62 | 2019 | |
| Allergan, INC. | $117.61 | 2019 | |
| Gilead Sciences, INC. | $115.17 | 2020 | |
| Corcept Therapeutics | $115.00 | 2024 | Korlym |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $113.16 | 2019 | |
| Vertex Pharmaceuticals Incorporated | $108.27 | 2025 | |
| Astellas Pharma US INC | $99.00 | 2021 | |
| Biocompatibles, INC. | $91.72 | 2019 | |
| Si-Bone, INC. | $88.80 | 2024 | |
| Integra Lifesciences Corporation | $87.52 | 2024 | Biodrestore, Medihoney, Biodfactor |
| E.R. Squibb & Sons, L.L.C. | $77.98 | 2022 | |
| Lifenet Health | $55.55 | 2025 | Allograft Vmis Delivery System, Pliafx Flo |
| Depuy Synthes Sales INC. | $54.03 | 2025 | |
| Dexcom, INC. | $18.97 | 2023 | Dexcom G6 Transmitter |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Moshir Jacob listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.